CECCHI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.040
EU - Europa 5.420
AS - Asia 3.434
SA - Sud America 580
AF - Africa 94
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.623
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.928
RU - Federazione Russa 1.634
PL - Polonia 1.564
SG - Singapore 867
CN - Cina 826
HK - Hong Kong 514
IT - Italia 468
BR - Brasile 464
VN - Vietnam 464
IE - Irlanda 437
SE - Svezia 367
KR - Corea 299
DE - Germania 223
FI - Finlandia 170
UA - Ucraina 151
FR - Francia 149
GB - Regno Unito 142
IN - India 127
JO - Giordania 91
CA - Canada 64
ID - Indonesia 55
AU - Australia 53
AR - Argentina 44
BD - Bangladesh 39
ES - Italia 39
JP - Giappone 38
MX - Messico 30
NL - Olanda 29
MA - Marocco 27
IQ - Iraq 22
TR - Turchia 20
EC - Ecuador 14
PY - Paraguay 14
CO - Colombia 13
PK - Pakistan 13
RO - Romania 12
VE - Venezuela 12
CI - Costa d'Avorio 11
ZA - Sudafrica 11
DZ - Algeria 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 7
IL - Israele 7
PH - Filippine 7
SC - Seychelles 7
AT - Austria 6
BE - Belgio 6
CH - Svizzera 6
CL - Cile 6
KE - Kenya 6
PE - Perù 6
EG - Egitto 5
HN - Honduras 5
IR - Iran 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
NG - Nigeria 4
SA - Arabia Saudita 4
UY - Uruguay 4
BW - Botswana 3
CZ - Repubblica Ceca 3
LT - Lituania 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
AZ - Azerbaigian 2
BO - Bolivia 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GT - Guatemala 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
RS - Serbia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
BS - Bahamas 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MU - Mauritius 1
NI - Nicaragua 1
OM - Oman 1
SI - Slovenia 1
SN - Senegal 1
VG - Isole Vergini Britanniche 1
Totale 17.623
Salva come PNG Salva come JPEG
Città #
Warsaw 1.562
Santa Clara 1.491
Fairfield 836
Ashburn 826
Singapore 603
Dublin 436
Hong Kong 417
Seattle 363
Woodbridge 361
Cambridge 335
Chandler 320
Seoul 293
Houston 290
Wilmington 266
Beijing 257
Jacksonville 244
San Jose 240
Ho Chi Minh City 133
Ann Arbor 127
Hefei 126
Los Angeles 117
Council Bluffs 116
Princeton 103
Lawrence 100
The Dalles 97
Altamura 95
Buffalo 95
Lauterbourg 93
Hanoi 88
Mumbai 86
Boston 84
Florence 76
Helsinki 75
Dallas 68
Moscow 68
Munich 55
Dong Ket 48
Boardman 45
São Paulo 45
New York 43
San Diego 41
Medford 40
Melbourne 39
Jakarta 38
Tokyo 33
Turku 32
Rome 29
Shanghai 29
Phoenix 27
Redondo Beach 27
Clifton 23
Toronto 22
Da Nang 21
Norwalk 21
Frankfurt am Main 20
Kent 18
Milan 18
Paris 18
Barcelona 17
Orem 16
Ottawa 16
Montreal 15
London 14
Rio de Janeiro 14
Casablanca 13
Guangzhou 13
Haiphong 13
Nuremberg 13
Belo Horizonte 12
Brasília 12
Long Branch 12
West Jordan 12
Abidjan 11
Amman 10
Asunción 10
Chicago 10
Madrid 10
Thái Bình 10
Buenos Aires 9
Chennai 9
Lappeenranta 9
Andover 8
Biên Hòa 8
Frankfurt Am Main 8
Hillsboro 8
Hải Dương 8
Izmir 8
St Petersburg 8
Atlanta 7
Auburn Hills 7
Baghdad 7
Brooklyn 7
Curitiba 7
Denver 7
Falls Church 7
Jersey City 7
Johannesburg 7
Naples 7
Porto Alegre 7
Prato 7
Totale 12.039
Salva come PNG Salva come JPEG
Nome #
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. 339
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils 332
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy 309
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. 301
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. 300
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy 282
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations 280
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy 276
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy 272
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 260
Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care 249
International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) 235
Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil 232
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study 228
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 220
Malattia di Anderson-Fabry 219
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy 218
An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy 217
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) 213
Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment 211
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 208
CHARACTERISTICS OF MYOCARDIAL HYPERTROPHY IN FRIEDREICH'S ATAXIA. CLINICO-INSTRUMENTAL STUDY IN 10 PATIENTS AND REVIEW OF THE LITERATURE 208
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy 208
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy 204
Beta-Blockers for Prevention of Exercise-induced Left Ventricular Outflow Obstruction in Patients with Hypertrophic Cardiomyopathy 204
Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C 203
Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy 200
MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol 197
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 195
Hypertrophic cardiomyopathy: prevalence of disease-specific red flags 190
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 189
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions 187
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 182
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 179
Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®) 179
HYPERTROPHIC CARDIOMYOPATHY 175
European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology 175
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. 174
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. 173
Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. 173
An expert consensus document on the management of cardiovascular manifestations of Fabry disease 172
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy 171
ARRHYTHMIAS ASSOCIATED WITH HYPERTROPHIC CARDIOMYOPATHY 168
Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy 166
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy 165
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. 161
CLINICAL PROFILE OF STROKE IN 900 PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 158
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy 158
The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy 158
Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy 157
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression 157
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 156
Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy 155
Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening 152
Echocardiographic features of right ventricular infarction. 151
Cardiomiopatie, Miocarditi e Pericarditi 149
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy 148
RELEVANCE OF CORONARY MICROVASCULAR FLOW IMPAIRMENT TO LONG TERM REMODELING AND SYSTOLIC DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY 147
Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in Tuscany 147
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. 146
Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy 145
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis 143
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal 143
Stage-specific therapy for hypertrophic cardiomyopathy 141
Right ventricular infarction: clinical, hemodynamic, mono- and two-dimensional echocardiographic features. 140
'End-stage' hypertrophic cardiomyopathy: from mystery to model 139
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. 138
MAXIMUM LEFT VENTRICULAR THICKNESS AND RISK OF SUDDEN DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 137
IMPACT OF ATRIAL FIBRILLATION ON THE CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY 137
THE ITALIAN REGISTRY FOR HYPERTROPHIC CARDIOMYOPATHY: A NATIONWIDE SURVEY 136
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy 135
RISK OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY ASSESSED BY SIGNAL AVERAGED P WAVE DURATION 134
Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy 134
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy 133
Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes 133
TRANSIENT ASYMMETRIC VENTRICULAR SEPTAL HYPERTROPHY IN THE NEWBORN UNASSOCIATED WITH MATERNAL DIABETES 132
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy 130
EPIDEMIOLOGY OF HYPERTROPHIC CARDIOMYOPATHY-RELATED DEATH: REVISITED IN A LARGE NON- REFERRAL-BASED PATIENT POPULATION 130
HYPERTROPHIC CARDIOMYOPATHY IN TUSCANY: CLINICAL COURSE AND OUTCOME IN AN UNSELECTED REGIONAL POPULATION 127
Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy 127
Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy 126
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy 124
Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy 123
CARDIOMIOPATIA IPERTROFICA 122
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy) 120
THE NEED FOR EUROPEAN REGISTRIES IN INHERITED CARDIOMYOPATHIES 118
Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanism and clinical consequences 116
Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management 114
Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy 112
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. 112
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy 111
CLINICAL UTILITY AND SAFETY OF EXERCISE TESTING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 111
Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy 109
RISK FACTORS AND STRATIFICATION FOR SUDDEN CARDIAC DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 107
EFFECT OF VERAPAMIL ON ABSOLUTE MYOCARDIAL BLOOD FLOW IN HYPERTROPHIC CARDIOMYOPATHY 106
CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY IN A NON SELECTED POPULATION. EXPERIENCE OF THE ITALIAN MULTICENTER CARDIOMYOPATHY STUDY 106
Layman electrocardiographic screening using smartphone-based multiple‑lead ECG device in school children 104
PROGNOSTIC VALUE OF NON-SUSTAINED VENTRICULAR TACHYCARDIA AND THE POTENTIAL ROLE OF AMIODARONE TREATMENT IN HYPERTROPHIC CARDIOMIYOPATHY: ASSESSMENT IN AN UNSELECTED NON-REFERRAL BASEDE PATIENT POPULATION 104
Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy 100
DIASTOLIC TIME INTERVALS BEFORE AN AFTER NADOLOL IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 99
Totale 17.096
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.821
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.821
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021206 0 0 0 0 0 0 0 0 0 0 66 140
2021/2022723 32 33 66 28 29 43 29 46 46 36 151 184
2022/20231.694 169 272 89 95 131 315 245 69 220 14 61 14
2023/2024590 23 72 118 36 38 78 18 109 15 32 20 31
2024/20254.453 165 481 267 680 1.294 561 63 305 198 132 168 139
2025/20264.978 478 760 436 719 572 221 609 312 359 323 189 0
Totale 17.720